The PD-1/PD-L1 pathway has shown promising clinical success as a cancer immunotherapy
target. Proteina’s PPI technology can help redesign the existing immunotherapy by measuring the activation of target pathways including PD-1, PD-L1 and other potential candidates such as CTLA-4, CD3, CD80, and CD40. To see more immune targets in Proteina’s library, see Target.
Our automated measuring equipment for single molecule co-IP assays can measure the activation of target proteins to find drug candidates that can potently inhibit TKIs. Currently we can screen approximately 200 drugs with our PPI library, and we are developing a High-Throughput PPI screening system for potential TKI inhibitors.
Insurers, pharmaceuticals, investors, research centers and whoever wants to collaborate with us, please feel free to contact us.